---
schema_version: "secwatch.filing_event.v1"
accession: "0001398733-26-000041"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2026-08-11T20:06:07+00:00"
generated_at: "2026-08-11T20:09:00.176544+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aquestive Q2 revenue up 38% to $13.8M; Anaphylm NDA resubmission on track for Q3 2026

## Summary
- Q2 revenue $13.8M vs $10.0M; manufacture/supply $11.9M, license/royalty $1.3M.
- Net loss $22.9M ($0.18/sh) includes $11.7M one-time debt extinguishment; ex-item net loss $11.2M.
- Non-GAAP adjusted EBITDA loss improved to $5.2M from $9.3M; cash $98.5M at June 30.
- Anaphylm PK study met primary endpoints; human factors study improved; NDA resubmission on track for Q3 2026.
- FY2026 guidance unchanged: revenue $46-50M, adj. EBITDA loss $35-30M; manufacturing 48M doses vs 37M.

## SEC filing metadata
- accession: 0001398733-26-000041
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2026-08-11T20:06:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/0001398733-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/aqst-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001398733-26-000041
- JSON: https://secwatch.observer/filing/0001398733-26-000041.json
- Plain text: https://secwatch.observer/filing/0001398733-26-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.